Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy

J Acquir Immune Defic Syndr. 2024 Apr 15;95(5):e8-e11. doi: 10.1097/QAI.0000000000003385. Epub 2024 Mar 11.

Jienchi Dorward^{1

2}, Yukteshwar Sookrajh³, Richard Lessells^{2

4}, Elliot Bulo³, Nicola Bodley², Lavanya Singh⁴, Pravikrishnen Moodley⁵, Natasha Samsunder², Paul K Drain^{6

7

8}, Gail Hayward¹, Christopher C Butler¹, Nigel Garrett^{2

9}

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
² Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
³ eThekwini Municipality Health Unit, Durban, South Africa.
⁴ KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa.
⁵ Department of Virology, University of KwaZulu-Natal and National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa.
⁶ Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, WA.
⁷ Department of Medicine, School of Medicine, University of Washington, Seattle, WA.
⁸ Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA; and.
⁹ Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.

Abstract

Supplemental Digital Content is Available in the Text.